Background: This study aimed to evaluate IgG and IgM levels in COVID-19 recurrence. Methods: The serum antibody levels and clinical data from 73 healthcare workers with SARS-CoV-2 divided into seroconverted (n=51) and non-seroconverted (n=22) groups were assessed. The presence of specific anti-nucleocapsid (anti-N) IgM and IgG for SARS-CoV-2 was evaluated. IgG antibodies to the SARS-CoV-2 spike receptor-binding domain were used to confirm non-seroconversion in all negative anti-N. Results: Four recurrent cases displayed mild symptoms and were non-seroconverted until the recurrence of symptoms. Conclusions: Undetectable anti-nucleocapsid IgM and IgG levels may be correlated with symptomatic COVID-19 recurrence.
CITATION STYLE
Gouvea, M. da P. G., Moulaz, I. R., Gouveia, T. M., Lança, K. E. M., Lacerda, B. S. de P., Thompson, B. P., … Valim, V. (2022). Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence. Revista Da Sociedade Brasileira de Medicina Tropical, 55. https://doi.org/10.1590/0037-8682-0106-2022
Mendeley helps you to discover research relevant for your work.